Caribou Biosciences, Inc. (CRBU)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Caribou Biosciences, Inc. reported revenue of $11.16M, up 11.7% from the prior year. The company ran a net loss, with a net margin of -1327.4%. It held $175.37M in total assets against $53.19M in total liabilities.
Key ratios (FY2025)
-1329.4%
Operating margin
-1327.4%
Net margin
-121.2%
Return on equity
+11.7%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11.16M | $9.99M | $34.48M | $13.85M | $9.60M | $12.36M | $5.79M | — |
| Operating Income | -$148.34M | -$166.62M | -$116.06M | -$106.40M | -$66.98M | -$36.12M | -$34.30M | — |
| Net Income | -$148.12M | -$149.10M | -$102.07M | -$99.42M | -$66.92M | -$34.31M | -$23.43M | — |
| EPS (Diluted) | $-1.59 | $-1.65 | $-1.38 | $-1.64 | $-2.11 | — | — | — |
| Total Assets | $175.37M | $313.31M | $432.21M | $373.76M | $442.36M | $36.05M | — | — |
| Total Liabilities | $53.19M | $60.36M | $63.81M | $72.89M | $54.53M | $18.16M | — | — |
| Shareholders' Equity | $122.17M | $252.95M | $368.40M | $300.87M | $387.82M | -$23.44M | $7.46M | $29.95M |
| Cash & Equivalents | $12.36M | $16.29M | $51.16M | $58.34M | $240.42M | $15.95M | $41.07M | — |
| Operating Cash Flow | -$110.99M | -$138.20M | -$93.29M | -$90.97M | -$32.52M | -$33.22M | -$32.01M | — |
| Capital Expenditures | $1.36M | $4.88M | $11.61M | $6.45M | $2.12M | $317.0K | $884.0K | — |
| Shares Outstanding | 95.14M | 92.38M | 88.45M | 61.03M | 60.26M | 9.71M | — | — |